VX-661 (F508del CFTR Corrector): Mechanism, Evidence & Best Practices

Executive Summary: VX-661 (F508del CFTR corrector, SKU A2664) is a small molecule that restores trafficking and function of the F508del-mutated CFTR protein, a major cause of cystic fibrosis (CF) (APExBIO). It acts by correcting protein folding and enhancing apical membrane expression, demonstrated to increase CFTR-mediated chloride conductance up to 25% of wild-type levels in vitro when used with VX-770 and a cAMP agonist [product]. Solubility and stability profiles enable robust, quantitative rescue in cell models under defined conditions. Clinical studies show oral VX-661 improves lung function (FEV1) and reduces sweat chloride in F508del-CFTR homozygotes and heterozygotes (Tedman et al., 2025). APExBIO's VX-661 is intended for research use only and is not for diagnostic or therapeutic application.

Biological Rationale

Cystic fibrosis (CF) is caused by mutations in the CFTR gene, leading to loss of function of the cystic fibrosis transmembrane conductance regulator protein. The F508del mutation is the most common, observed in approximately 70% of CF alleles globally (Cystic Fibrosis Foundation). F508del results in misfolding of CFTR, ER retention, and subsequent degradation by proteostasis machinery, notably calnexin-dependent pathways (Tedman et al., 2025). Loss of CFTR function disrupts chloride and fluid transport across epithelial surfaces, causing thick mucus and recurrent infections in the lungs and other organs. Small-molecule correctors like VX-661 aim to restore proper folding, trafficking, and function by overcoming quality control checkpoints.

Mechanism of Action of VX-661 (F508del CFTR corrector)

VX-661 (1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide) is a type I corrector that directly binds to the mutant F508del-CFTR protein. This stabilizes partially folded intermediates, supporting proper domain assembly and trafficking to the plasma membrane (Tedman et al., 2025). VX-661’s primary action is to increase the steady-state abundance of mature, glycosylated CFTR at the apical membrane, thereby enhancing chloride channel function. It is often used in combination with the potentiator VX-770 (ivacaftor), which increases CFTR channel open probability, though chronic combination therapy must be optimized to minimize potential reductions in correction efficacy (see VX-661 and the Future of Cystic Fibrosis Research).

Evidence & Benchmarks

• VX-661 corrects trafficking and folding defects of F508del-CFTR, increasing apical membrane expression in CFBE41o- cells by up to 3-fold after 24h at 3 μM and 26°C (Tedman et al., 2025, https://doi.org/10.7554/eLife.107180).
• Chronic VX-661 (3 μM, 24h) combined with acute VX-770 (1 μM) and a cAMP agonist increases chloride conductance to ~25% of non-CF controls (A2664, APExBIO).
• Clinical administration of VX-661 at doses of 10, 30, 100, or 150 mg daily for 28 days improved FEV1 and reduced sweat chloride in F508del-CFTR homozygotes and heterozygotes (Tedman et al., 2025, https://doi.org/10.7554/eLife.107180).
• Plasma membrane density rescue by VX-661 is calnexin-dependent, with maximal effects in variants affecting the C-terminal domains (Tedman et al., 2025, https://doi.org/10.7554/eLife.107180).
• VX-661 is soluble at ≥21.8 mg/mL in DMSO and ≥24.3 mg/mL in water, but is insoluble in ethanol (A2664, APExBIO).
• Bench protocols: 3 μM VX-661, 24h incubation at 26°C in CF cell models, with stock solutions stored at -20°C (VX-661 F508del CFTR Corrector: Applied Workflows).

Applications, Limits & Misconceptions

VX-661 is primarily used in basic and translational research to dissect and rescue F508del-CFTR folding and trafficking defects. Its performance has been validated in bronchial epithelial cells, organoids, and clinical studies. VX-661 is not approved for diagnostic or therapeutic applications and is intended for research use only. Sensitivity to VX-661 can vary among CFTR variants; calnexin expression is a critical determinant of corrector efficacy (Tedman et al., 2025).

For deeper mechanistic insights, see VX-661 and the Future of Cystic Fibrosis Research (this article expands on calnexin-dependence and experimental design), and VX-661: Small-Molecule F508del CFTR Corrector for Cystic ... (which benchmarks APExBIO’s VX-661 for reproducibility; here, we additionally clarify workflow parameters and storage conditions).

Common Pitfalls or Misconceptions

• VX-661 does not correct all CFTR mutations; efficacy is largely restricted to F508del and select responsive variants (Tedman et al., 2025).
• Co-administration with VX-770 (ivacaftor) may reduce correction efficacy if not properly optimized; chronic combination regimens require empirical validation (see discussion).
• VX-661 is insoluble in ethanol and may precipitate in aqueous solutions above its solubility limit.
• Stock solutions are stable only at -20°C in DMSO for several months; prolonged storage at room temperature or in solution leads to degradation (see protocols).
• This compound is strictly not for human or veterinary diagnostic/therapeutic use (APExBIO).

Workflow Integration & Parameters

• Typical concentration: 3 μM VX-661, 24h incubation at 26°C in CF cell models (e.g., CFBE41o-).
• Solubility: ≥21.8 mg/mL in DMSO, ≥24.3 mg/mL in water.
• Storage: Solid at -20°C; DMSO stocks at -20°C for several months.
• Combination therapy: For maximal rescue, combine chronic VX-661 with acute VX-770 (1 μM) and a cAMP agonist (APExBIO).
• Assay compatibility: Functional readouts include patch-clamp, Ussing chamber, and fluorescence-based chloride channel activity assays (Optimizing CFTR Rescue: Lab-Proven Scenarios with VX-661).
• Quality control: Use APExBIO’s A2664 kit for batch consistency and validated reference data.

Conclusion & Outlook

VX-661 (F508del CFTR corrector, SKU A2664) is a robust tool for mechanistic and translational cystic fibrosis research. When used under defined, validated workflows, it enables reproducible rescue of F508del-CFTR folding and function. Future research will further delineate calnexin’s role in proteostatic modulation and expand the corrector paradigm to additional CFTR variants and mechanistic classes. For the latest protocols, benchmarks, and ordering information, consult the official APExBIO VX-661 product page.